Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) EBITDA: 2016-2025

Historic EBITDA for UroGen Pharma (URGN) over the last 10 years, with Sep 2025 value amounting to -$33.3 million.

  • UroGen Pharma's EBITDA fell 42.40% to -$33.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$164.9 million, marking a year-over-year decrease of 43.34%. This contributed to the annual value of -$126.8 million for FY2024, which is 24.19% down from last year.
  • UroGen Pharma's EBITDA amounted to -$33.3 million in Q3 2025, which was up 33.27% from -$49.9 million recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's EBITDA peaked at -$21.9 million during Q3 2023, and registered a low of -$49.9 million during Q2 2025.
  • Over the past 3 years, UroGen Pharma's median EBITDA value was -$32.3 million (recorded in 2024), while the average stood at -$32.4 million.
  • In the last 5 years, UroGen Pharma's EBITDA skyrocketed by 30.29% in 2021 and then crashed by 49.56% in 2025.
  • Quarterly analysis of 5 years shows UroGen Pharma's EBITDA stood at -$28.5 million in 2021, then decreased by 1.19% to -$28.8 million in 2022, then climbed by 10.24% to -$25.9 million in 2023, then tumbled by 45.70% to -$37.7 million in 2024, then tumbled by 42.40% to -$33.3 million in 2025.
  • Its EBITDA stands at -$33.3 million for Q3 2025, versus -$49.9 million for Q2 2025 and -$43.9 million for Q1 2025.